Supplementary Table S3 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts

Supplementary Table S3 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts

<p>List of differentially expressed genes associated with EMK, INT and IMP profile.</p>

保存先:

書誌詳細
第一著者:	Gabriele Todisco (15127828) (author)
その他の著者:	Maria Creignou (15127831) (author), Elsa Bernard (15127822) (author), Ann-Charlotte Björklund (17141972) (author), Pedro Luis Moura (17141975) (author), Bianca Tesi (17141978) (author), Teresa Mortera-Blanco (17141981) (author), Birgitta Sander (17141984) (author), Monika Jansson (17141987) (author), Gunilla Walldin (17141990) (author), Indira Barbosa (17141993) (author), Susanne E. Reinsbach (17141996) (author), Isabel Juliana Hofman (17141999) (author), Christer Nilsson (17142002) (author), Tetsuichi Yoshizato (17142005) (author), Marios Dimitriou (17142008) (author), David Chang (17142011) (author), Svannildur Olafsdottir (17142014) (author), Sigita Venckute Larsson (17142017) (author), Magnus Tobiasson (17142020) (author), Luca Malcovati (17142023) (author), Petter Woll (17142026) (author), Sten Eirik W. Jacobsen (17142029) (author), Elli Papaemmanuil (9710965) (author), Eva Hellström-Lindberg (17142032) (author)
出版事項:	2025
主題:	Cancer Therapeutic Research and Development Clinical Research and Trials Hematological Cancers Leukemias Precision Medicine Translational Research
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S1 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
著者:: Gabriele Todisco (15127828)
出版事項: (2025)

Supplementary Table S2 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
著者:: Gabriele Todisco (15127828)
出版事項: (2025)

Supplementary Table S4 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
著者:: Gabriele Todisco (15127828)
出版事項: (2025)

Supplementary Table S5 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
著者:: Gabriele Todisco (15127828)
出版事項: (2025)

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
著者:: Ibrahim Aldoss (15055961)
出版事項: (2025)

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
著者:: Ibrahim Aldoss (15055961)
出版事項: (2025)

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
著者:: Ibrahim Aldoss (15055961)
出版事項: (2025)

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
著者:: Ibrahim Aldoss (15055961)
出版事項: (2025)

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
著者:: Ibrahim Aldoss (15055961)
出版事項: (2025)

Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
著者:: Wei Chen (15053713)
出版事項: (2025)

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
著者:: Wei Chen (15053713)
出版事項: (2025)

Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
著者:: Wei Chen (15053713)
出版事項: (2025)

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
著者:: Anna Eriksson (15352461)
出版事項: (2025)

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
著者:: Anna Eriksson (15352461)
出版事項: (2025)

Supplementary Tables S1-S11 from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic <i>TP53</i>-Mutant Clonal Hematopoiesis
著者:: Rathana Kim (15135915)
出版事項: (2025)

Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
著者:: Amy C. Degnim (15106462)
出版事項: (2025)

Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
著者:: Amy C. Degnim (15106462)
出版事項: (2025)

Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
著者:: Amy C. Degnim (15106462)
出版事項: (2025)

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
著者:: Morten Lapin (15056728)
出版事項: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
著者:: Morten Lapin (15056728)
出版事項: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
著者:: Morten Lapin (15056728)
出版事項: (2025)

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
著者:: Naveen S. Vasudev (15057037)
出版事項: (2025)

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
著者:: Naveen S. Vasudev (15057037)
出版事項: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
著者:: Robert L. Hollis (15034814)
出版事項: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
著者:: Robert L. Hollis (15034814)
出版事項: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
著者:: Robert L. Hollis (15034814)
出版事項: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
著者:: Robert L. Hollis (15034814)
出版事項: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
著者:: Robert L. Hollis (15034814)
出版事項: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
著者:: Robert L. Hollis (15034814)
出版事項: (2025)

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
著者:: Shih-Shih Chen (15314296)
出版事項: (2025)

Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
著者:: Shih-Shih Chen (15314296)
出版事項: (2025)

Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
著者:: Shih-Shih Chen (15314296)
出版事項: (2025)

Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
著者:: Shih-Shih Chen (15314296)
出版事項: (2025)

Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
著者:: Shih-Shih Chen (15314296)
出版事項: (2025)

Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
著者:: Shih-Shih Chen (15314296)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jho95e5mbfv3v5sor66nrrjiht